PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
19 hedge funds and large institutions have $690K invested in PLx Pharma Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
30% more capital invested
Capital invested by funds: $530K → $690K (+$160K)
0% more funds holding
Funds holding: 19 → 19 (0)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$264K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
+$44.1K |
| 3 |
BlackRock
New York
|
+$24.3K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$20.8K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.79K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$34.1K |
| 2 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$24.9K |
| 3 |
Bank of New York Mellon
New York
|
-$23K |
| 4 |
Morgan Stanley
New York
|
-$326 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$130 |
PLXP Hedge Fund Activity: Q1 2017 in Review
19 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q1 2017, worth a combined $690K — up 30% from $530K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PLXP positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 5 trimmed.
The largest buyer was Park West Asset Management, opening a new position worth an estimated $264K. The largest seller was Northern Trust, cutting an estimated $34.1K.
- 19 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q1 2017, unchanged from Q4 2016.
- Funds reported $690K of PLx Pharma Inc. Common Stock stock for Q1 2017, up 30% quarter-over-quarter.
- 5 funds opened new PLx Pharma Inc. Common Stock positions in Q1 2017 and 2 closed out, a net change of +3 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q1 2017 was Park West Asset Management, an estimated $264K added.
- The largest PLx Pharma Inc. Common Stock seller in Q1 2017 was Northern Trust, an estimated $34.1K sold.
Based on aggregated 13F filings for Q1 2017.